AgeX Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
AGE
- Investments
-
2
- Share Price
-
$0.70
- (As of Monday Closing)
AgeX Therapeutics General Information
Description
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Contact Information
- 1010 Atlantic Avenue
- Suite 102
- Alameda, CA 94501
- United States
AgeX Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.70 | $0.68 | $0.37 - $1.00 | $25.8M | 38M | 20.8K | -$0.30 |
AgeX Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 53,549 | 36,078 | 51,988 | 61,608 |
| Revenue | 36 | 34 | 144 | 361 |
| EBITDA | (7,237) | (7,055) | (7,354) | (8,740) |
| Net Income | (11,084) | (10,462) | (8,675) | (10,865) |
| Total Assets | 12,277 | 3,241 | 3,154 | 3,925 |
| Total Debt | 33,011 | 18,124 | 13,202 | 6,296 |
AgeX Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AgeX Therapeutics Comparisons
Industry
Financing
Details
000000
00000
AgeX Therapeutics Competitors (51)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
| 000000000 | Corporation | Melbourne, Australia | 00 | 00000 | 000000000 | 00000 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 0000 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
AgeX Therapeutics Patents
AgeX Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022207066-A1 | Methods for the ex vivo induction of tissue regeneration in microbiopsies | Pending | 12-Jan-2021 | 000000000 | |
| CA-3208140-A1 | Methods for the ex vivo induction of tissue regeneration in microbiopsies | Pending | 12-Jan-2021 | 000000000 | |
| AU-2021210986-A1 | Therapeutic exosomes and method of producing them | Pending | 22-Jan-2020 | 000000000 | |
| CA-3168806-A1 | Therapeutic exosomes and method of producing them | Pending | 22-Jan-2020 | 000000000 | |
| EP-4093408-A1 | Therapeutic exosomes and method of producing them | Pending | 22-Jan-2020 | A61K9/5184 |
AgeX Therapeutics Executive Team (9)
AgeX Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Annalisa Jenkins MD | Self | Board Member | 000 0000 |
| Gregory Bailey MD | Self | Board Member | 000 0000 |
| Joanne Hackett | AgeX Therapeutics | Chief Executive Officer & Chairman | 000 0000 |
AgeX Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
AgeX Therapeutics Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 30-Mar-2023 | 0000000 00 | Pharmaceuticals | 000000 00 | |
| Escape Therapeutics (UniverCyte Technology Patent in Silicon Valley, California) | 16-Aug-2019 | Corporate Asset Purchase | Buildings and Property | 0000000 0 |
AgeX Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 30, 2020
53.41 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 13,035
Rank
Percentile
Pharmaceuticals
Industry
00 of 806
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 383
Rank
Percentile
